Topics

FDA to split Blueprint’s cancer drug application in two

11:38 EDT 28 Oct 2019 | MedCity News

Shares of the company fell about 5 percent Monday following news that the FDA would review the drug avapritinib separately for two indications of gastrointestinal stromal tumor.

Original Article: FDA to split Blueprint’s cancer drug application in two

NEXT ARTICLE

More From BioPortfolio on "FDA to split Blueprint’s cancer drug application in two"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...